HMHelfried Metzler

Helfried Metzler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Helfried Metzler has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Anaesthesia in patients with drug-eluting stents

    by Helfried Metzler, Kurt Huber, Sibylle Kozek-Langenecker

    The management of patients with recent coronary artery stents presenting for noncardiac surgery has become a major topic of interest and concern for all perioperative caregivers. This review will update recent reports and particularly new guidelines as well as recommendations. Based on the available literature all experts recommend avoiding premature discontinuation of antiplatelet drug therapy if possible except for a few surgical procedures. Drug-eluting stents obviously carry more risks than bare-metal stents. Anaesthesiologists may understand the specific problem of drug-eluting stents, the recent debate among cardiologists and the implications for the perioperative scenario.


  • Koronare Stents, duale Antiplättchentherapie und die perioperative Problematik

    by H. Metzler, K. Huber, S. Kozek-Langenecker, M.N. Vicenzi, A. Münch

    Bei perkutaner koronarer Intervention werden in bis zu 90% der Fälle Koronarstents implantiert. Sie erfordern typabhängig eine duale Antiplättchentherapie (Clopidogrel und Acetylsalicylsäure). Die Therapiedauer liegt bei 3–4 Wochen bzw. 6–12 Monaten bei Bare-Metal- bzw. Drug-Eluting-Stents. Absetzen der dualen Antiplättchentherapie erhöht das Risiko einer Stentthrombose, ihre Weiterführung das einer relevanten Blutung im Operationsgebiet. Das perioperative Vorgehen stützt sich auf Empfehlungen anästhesiologischer und kardiologischer Gesellschaften. Bei Eingriffen mit hohem Blutungsrisiko kann von chirurgischer Seite ein Absetzen beider Substanzen erforderlich sein, bei hohem Thromboserisiko sollten beide Medikamente, zumindest aber Acetylsalicylsäure, bis zum Operationstag gegeben werden. Für die Durchführung einer Regionalanästhesie existieren Empfehlungen von nationalen Gesellschaften. Patienten, die nach koronarer Stentimplantation unter dualer Antiplättchentherapie stehen, profitieren von einer interdisziplinären Betreuung durch Anästhesiologen, Operateur und Kardiologen. Up to 90% of all percutaneous coronary interventions include coronary artery stenting. Dual antiplatelet therapy, usually involving acetylsalicyl acid combined with clopidogrel, is mandatory for patients with coronary artery stents. The duration of antiplatelet therapy for bare metal stents is 3–4 weeks, for drug eluting stents 6–12 months. Preoperative discontinuation of both drugs increases the risk of stent thrombosis, continuation the risk of relevant bleeding. According to the recommendations of anaesthesiological and cardiological societies, perioperative management has to balance the risk of bleeding vs stent thrombosis. Surgery involving a high risk of bleeding can require the discontinuance of both substances. In cases of high thrombosis risk, at least the acetylsalicyl acid should be continued until the day of surgery. For patients under antiplatelet therapy scheduled for local anaesthesia, national recommendations exist. A close collaboration between the anaesthesiologist, cardiologist and surgeon is essential for appropriate pre-, intra- and postoperative management.